Vladislav V. Semerikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vladislav V. Semerikov has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Lyudmila V. Sofronova
E.A. Vagner Perm State Medical University
9 shared publications - Elena S. Zubova
Regional Children's Clinical Hospital
6 shared publications - Nina Olegovna Postanogova
E.A. Vagner Perm State Medical University
6 shared publications - Leyla Seymurovna Namazova-Baranova
Russian Scientific Surgery Center named after Academician B.V. Petrovskiy with the Russian Academy of Sciences, Moscow, Russia
4 shared publications - Nadezhda V. Yuminova
Research Institute of Vaccines and Sera named after I.I. Mechnikov
4 shared publications - Aleksei Yu. Rtishchev
Pirogov Russian National Research Medical University; Morozovskaya Children's City Clinical Hospital
3 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 25 (4) , 283-300
Immunogenicity, Reactogenicity, and Safety of CRM197-Conjugated Meningococcal A, C, W, Y Vaccine: Multicenter, Randomized, Phase III Trial
Background . Generalized forms of meningococcal disease caused by Neisseria meningitidis are characterized by rapid course and high mortality. The pathogen serogroup distribution varies between regions and changes over time, which determines the need for vaccines covering currently relevant serogroups A, C, W and Y. Licensed quadrivalent conjugate vaccines differ both in polysaccharide content and in carrier protein, which properties are considered among the factors shaping the T-dependent immune response. Objective. The aim of the study is to evaluate immunogenicity, reactogenicity, and safety of meningococcal conjugate vaccine MenACWY-CRM197 compared with previously licensed MenACWY-DT vaccine in healthy people aged 3–55 years. Methods. Multicenter, randomized, comparative, single-blind, parallel-group, phase III trial was conducted in 16 clinical centers among Russian Federation. All study participants were allocated 1:1 across three sequential age groups (I — 18–55 years, II — 11–17 years, III — 3–10 years). The transition between groups was performed after positive conclusion on vaccine safety according to interim safety data by independent data monitoring committee. Both vaccines were administered intramuscularly once at dosage of 0.5 ml. The primary endpoint was the proportion of participants achieving seroconversion based on serum bactericidal antibody (SBA) titers against meningococcal serogroups A, C, Y, and W at Visit 3 (Day 29 ± 1); non-inferiority was considered demonstrated if the lower bound of the 95% confidence interval (CI) for the difference in proportions exceeded –10%. Secondary endpoints (seroprotection at SBA titer > 1:4, geometric mean titers (GMT), reverse cumulative titer distribution curves) and safety outcomes were analyzed without adjustment for comparisons multiplicity; corresponding p-values are descriptive. Results . A total of 240 participants were randomized (120 per group); the per-protocol population comprised 239 participants. Seroconversion by Visit 3 was achieved in at least 98.33% of participants for each of the four meningococcal serogroups in both groups; and it was achieved in all participants for serogroups C and W. The lower bounds of the 95% CI for the proportions difference for meningococcal serogroup A (0.83%; 95% CI –3.82…5.72) and serogroup Y (–0.007%; 95% CI –4.51…4.47) exceeded the non-inferiority margin confirming the study hypothesis for the primary endpoint. SBA titers increased significantly from Visit 1 to Visit 3 for all serogroups in both groups (p < 0.001). No differences in GMT between groups were revealed for meningococcal serogroups A, W, and Y; while the post-vaccination GMT in the investigational vaccine group was higher (306.7 vs 222.9; p = 0.017) for serogroup C. The studied vaccine demonstrated favorable safety profile. At least one adverse event (AE) was reported in 53.33% of participants in the investigational vaccine group and in 56.67% of the reference group (p = 0.604). No differences between groups were revealed in the distribution of AE by severity, causal relationship, or outcomes in the pooled population. The distribution of AE by severity differed (ratio of mild AE 86.46% vs 73.68% in the comparison group; p = 0.033) in the analysis by age stratum, among adolescents aged 11–17 years in the MenACWY-CRM197 vaccine group; in children aged 3–10 years, systemic reactions were reported in 20.0% and 40.0% of participants, respectively (p = 0.051). No serious AE related to vaccination and no fatal outcomes were reported. Conclusion. In terms of seroconversion frequency against all four meningococcal serogroups, the MenACWY-CRM197 vaccine was non-inferior to the reference vaccine. Safety and reactogenicity profiles in the pooled population were comparable. The superior result of the investigational vaccine for secondary endpoints (GMT against meningococcal serogroup C) and the results of reactogenicity analysis by age stratum were obtained without controlling for type I error probability and require further study in specifically designed trials. The obtained data confirms the immunogenicity and acceptable tolerability of the MenACWY-CRM197 vaccine in individuals aged from 3 to 55 years. The study results allow us to consider using this vaccine for meningococcal infection prevention in children, adolescents, and adults as part of mass vaccination. Trial registration : protocol GNG-DE-III-24, version 1.0, August 15, 2024; clinical trial authorization by the Ministry of Health of Russian Federation No.532, November 07, 2024.
- 2 October 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 25 (4) , 283-300
Open AccessImmunogenicity, Reactogenicity, and Safety of CRM197-Conjugated Meningococcal A, C, W, Y Vaccine: Multicenter, Randomized, Phase III Trial
Background . Generalized forms of meningococcal disease caused by Neisseria meningitidis are characterized by rapid course and high mortality. The pathogen serogroup distribution varies between regions and changes over time, which determines the need for vaccines covering currently relevant serogroups A, C, W and Y. Licensed quadrivalent conjugate vaccines differ both in polysaccharide content and in carrier protein, which properties are considered among the factors shaping the T-dependent immune response. Objective. The aim of the study is to evaluate immunogenicity, reactogenicity, and safety of meningococcal conjugate vaccine MenACWY-CRM197 compared with previously licensed MenACWY-DT vaccine in healthy people aged 3–55 years. Methods. Multicenter, randomized, comparative, single-blind, parallel-group, phase III trial was conducted in 16 clinical centers among Russian Federation. All study participants were allocated 1:1 across three sequential age groups (I — 18–55 years, II — 11–17 years, III — 3–10 years). The transition between groups was performed after positive conclusion on vaccine safety according to interim safety data by independent data monitoring committee. Both vaccines were administered intramuscularly once at dosage of 0.5 ml. The primary endpoint was the proportion of participants achieving seroconversion based on serum bactericidal antibody (SBA) titers against meningococcal serogroups A, C, Y, and W at Visit 3 (Day 29 ± 1); non-inferiority was considered demonstrated if the lower bound of the 95% confidence interval (CI) for the difference in proportions exceeded –10%. Secondary endpoints (seroprotection at SBA titer > 1:4, geometric mean titers (GMT), reverse cumulative titer distribution curves) and safety outcomes were analyzed without adjustment for comparisons multiplicity; corresponding p-values are descriptive. Results . A total of 240 participants were randomized (120 per group); the per-protocol population comprised 239 participants. Seroconversion by Visit 3 was achieved in at least 98.33% of participants for each of the four meningococcal serogroups in both groups; and it was achieved in all participants for serogroups C and W. The lower bounds of the 95% CI for the proportions difference for meningococcal serogroup A (0.83%; 95% CI –3.82…5.72) and serogroup Y (–0.007%; 95% CI –4.51…4.47) exceeded the non-inferiority margin confirming the study hypothesis for the primary endpoint. SBA titers increased significantly from Visit 1 to Visit 3 for all serogroups in both groups (p < 0.001). No differences in GMT between groups were revealed for meningococcal serogroups A, W, and Y; while the post-vaccination GMT in the investigational vaccine group was higher (306.7 vs 222.9; p = 0.017) for serogroup C. The studied vaccine demonstrated favorable safety profile. At least one adverse event (AE) was reported in 53.33% of participants in the investigational vaccine group and in 56.67% of the reference group (p = 0.604). No differences between groups were revealed in the distribution of AE by severity, causal relationship, or outcomes in the pooled population. The distribution of AE by severity differed (ratio of mild AE 86.46% vs 73.68% in the comparison group; p = 0.033) in the analysis by age stratum, among adolescents aged 11–17 years in the MenACWY-CRM197 vaccine group; in children aged 3–10 years, systemic reactions were reported in 20.0% and 40.0% of participants, respectively (p = 0.051). No serious AE related to vaccination and no fatal outcomes were reported. Conclusion. In terms of seroconversion frequency against all four meningococcal serogroups, the MenACWY-CRM197 vaccine was non-inferior to the reference vaccine. Safety and reactogenicity profiles in the pooled population were comparable. The superior result of the investigational vaccine for secondary endpoints (GMT against meningococcal serogroup C) and the results of reactogenicity analysis by age stratum were obtained without controlling for type I error probability and require further study in specifically designed trials. The obtained data confirms the immunogenicity and acceptable tolerability of the MenACWY-CRM197 vaccine in individuals aged from 3 to 55 years. The study results allow us to consider using this vaccine for meningococcal infection prevention in children, adolescents, and adults as part of mass vaccination. Trial registration : protocol GNG-DE-III-24, version 1.0, August 15, 2024; clinical trial authorization by the Ministry of Health of Russian Federation No.532, November 07, 2024.
- Open Access
- 30 April 2026
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (2) , 127-138
Serological tests based on viral glycoproteins for detecting neutralizing antibodies to measles, mumps and rubella viruses
Introduction. Measles, mumps and rubella viruses are highly contagious viruses that can cause serious clinical outcomes, complications and death. Neutralizing antibodies against measles, mumps and rubella viruses are a good indicator of clinical protection against these infections, but they are difficult to measure. The aim. To develop a serological glycoprotein-based passive hemagglutination reaction (gpPHAR) tests for the detection of neutralizing antibodies to measles, mumps and rubella viruses. Materials and methods. Human and animal cell cultures from the collection of the I.I. Mechnikov Research Institute of Vaccines and Sera were used; vaccine strains of measles, mumps and rubella viruses; monoclonal antibodies to measles and rubella virus glycoproteins, human and animal immune sera; formalized sheep erythrocytes sensitized with viral glycoproteins; virus neuralization test (VNT), gpPHAR and gpELISA. Results. Viral glycoproteins of measles, mumps, and rubella were extracted from infected cell cultures. Comparative titrations of human and animal immune sera to measles, mumps, and rubella viruses in VNT, gpPHAR, and gpELISA have been performed. Unambiguous titers of neutralizing antibodies have been established. Titration of homologous and heterologous immune sera to three viruses was performed in the gpPHAR. The absence of cross-immunoreactivity to other viral agents has been established. The titers of the immune sera of patients with measles, mumps, and rubella infections were determined in the gpPHAR and gpELISA assays. Identical titers of neutralizing antibodies were found in both serological tests. Conclusion. The gpPHAR serological tests has been developed to evaluate neutralizing virus-specific antibodies to measles, mumps and rubella in patients.
- 30 April 2026
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (2) , 127-138
Open AccessSerological tests based on viral glycoproteins for detecting neutralizing antibodies to measles, mumps and rubella viruses
Introduction. Measles, mumps and rubella viruses are highly contagious viruses that can cause serious clinical outcomes, complications and death. Neutralizing antibodies against measles, mumps and rubella viruses are a good indicator of clinical protection against these infections, but they are difficult to measure. The aim. To develop a serological glycoprotein-based passive hemagglutination reaction (gpPHAR) tests for the detection of neutralizing antibodies to measles, mumps and rubella viruses. Materials and methods. Human and animal cell cultures from the collection of the I.I. Mechnikov Research Institute of Vaccines and Sera were used; vaccine strains of measles, mumps and rubella viruses; monoclonal antibodies to measles and rubella virus glycoproteins, human and animal immune sera; formalized sheep erythrocytes sensitized with viral glycoproteins; virus neuralization test (VNT), gpPHAR and gpELISA. Results. Viral glycoproteins of measles, mumps, and rubella were extracted from infected cell cultures. Comparative titrations of human and animal immune sera to measles, mumps, and rubella viruses in VNT, gpPHAR, and gpELISA have been performed. Unambiguous titers of neutralizing antibodies have been established. Titration of homologous and heterologous immune sera to three viruses was performed in the gpPHAR. The absence of cross-immunoreactivity to other viral agents has been established. The titers of the immune sera of patients with measles, mumps, and rubella infections were determined in the gpPHAR and gpELISA assays. Identical titers of neutralizing antibodies were found in both serological tests. Conclusion. The gpPHAR serological tests has been developed to evaluate neutralizing virus-specific antibodies to measles, mumps and rubella in patients.
- Open Access
- 13 March 2026
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 25 (1) , 48-53
Preventive Rotavirus Vaccination in a Defined Region: Implementation Under the Regional Immunization Schedule
Relevance. Rotavirus infection remains epidemiologically and economically significant to this day. Aim. To evaluate the preventive effectiveness of the rotavirus vaccine in the vaccination of young children. Materials and methods. This article presents a comparative analysis of rotavirus enteritis incidence across different age groups in the municipal district of «Berezniki City» during the pre-mass vaccination (2010–2018) and mass vaccination (2019–2024) periods. The comparison region was the Kudymkarsky Municipal District, where rotavirus immunization was not implemented. Results and discussion. The findings demonstrate a significant decrease in rotavirus enteritis incidence among residents of the «Berezniki City» municipal district during the mass vaccination period compared to the pre-vaccination era, confirming the high preventive efficacy of rotavirus enteritis immunization. Conclusion. The obtained data support the necessity of introducing mass vaccination against rotavirus infection in first-year infants within specific regions as the most effective tool for reducing morbidity and improving the epidemiological situation.
- 13 March 2026
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 25 (1) , 48-53
Open AccessPreventive Rotavirus Vaccination in a Defined Region: Implementation Under the Regional Immunization Schedule
Relevance. Rotavirus infection remains epidemiologically and economically significant to this day. Aim. To evaluate the preventive effectiveness of the rotavirus vaccine in the vaccination of young children. Materials and methods. This article presents a comparative analysis of rotavirus enteritis incidence across different age groups in the municipal district of «Berezniki City» during the pre-mass vaccination (2010–2018) and mass vaccination (2019–2024) periods. The comparison region was the Kudymkarsky Municipal District, where rotavirus immunization was not implemented. Results and discussion. The findings demonstrate a significant decrease in rotavirus enteritis incidence among residents of the «Berezniki City» municipal district during the mass vaccination period compared to the pre-vaccination era, confirming the high preventive efficacy of rotavirus enteritis immunization. Conclusion. The obtained data support the necessity of introducing mass vaccination against rotavirus infection in first-year infants within specific regions as the most effective tool for reducing morbidity and improving the epidemiological situation.
- Open Access
- 14 November 2025
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 42 (5) , 58-65
Effectiveness and safety of combination antiretroviral therapy schemes for acute HIV infection
Objective. To conduct a comparative study of efficacy and safety of treatment with nucleoside reverse transcriptase inhibitors (NRTIs) – phosphazide and tenofovir in patients with acute HIV infection. Materials and methods. A comparative study to evaluate the efficacy and safety of domestic drugs phosphazide and tenofovir in combination antiretroviral therapy regimens for acute HIV infection was conducted for 48 weeks in Perm Regional Center for AIDS and Infectious Diseases in 2017-2019. A total of 28 patients, divided into 2 groups, were included into the study. All patients underwent early diagnosis of HIV infection using enzyme immunoassay, immunoblotting, detection of HIV DNA and RNA by polymerase chain reaction (PCR); indicators of cellular immunity were determined – the level of CD4 + lymphocytes, assessment of clinical status before the start of the prescribed combination antiretroviral treatment and after 2, 4, 12, 24, 36 and 48 weeks. Results. High virological, immunological, clinical efficacy and safety of the use of antiretroviral therapy (ART) regimens containing phosphazide or tenofovir in combination with lamivudine and efavirenz in the treatment of the acute stage of HIV infection have been demonstrated. These drugs can be recommended for use in the first-line therapy. Conclusions. The conducted study allows us to recommend the scheme of using phosphazide in combination with lamivudine and efavirenz for the first-line therapy in HIV-infected patients. Further optimization of antiretroviral therapy of HIV infection based on phosphazide involves creation of a combination of fixed doses with a frequency of use once a day for the treatment of HIV/AIDS as new dosage forms.
- 14 November 2025
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 42 (5) , 58-65
Open AccessEffectiveness and safety of combination antiretroviral therapy schemes for acute HIV infection
Objective. To conduct a comparative study of efficacy and safety of treatment with nucleoside reverse transcriptase inhibitors (NRTIs) – phosphazide and tenofovir in patients with acute HIV infection. Materials and methods. A comparative study to evaluate the efficacy and safety of domestic drugs phosphazide and tenofovir in combination antiretroviral therapy regimens for acute HIV infection was conducted for 48 weeks in Perm Regional Center for AIDS and Infectious Diseases in 2017-2019. A total of 28 patients, divided into 2 groups, were included into the study. All patients underwent early diagnosis of HIV infection using enzyme immunoassay, immunoblotting, detection of HIV DNA and RNA by polymerase chain reaction (PCR); indicators of cellular immunity were determined – the level of CD4 + lymphocytes, assessment of clinical status before the start of the prescribed combination antiretroviral treatment and after 2, 4, 12, 24, 36 and 48 weeks. Results. High virological, immunological, clinical efficacy and safety of the use of antiretroviral therapy (ART) regimens containing phosphazide or tenofovir in combination with lamivudine and efavirenz in the treatment of the acute stage of HIV infection have been demonstrated. These drugs can be recommended for use in the first-line therapy. Conclusions. The conducted study allows us to recommend the scheme of using phosphazide in combination with lamivudine and efavirenz for the first-line therapy in HIV-infected patients. Further optimization of antiretroviral therapy of HIV infection based on phosphazide involves creation of a combination of fixed doses with a frequency of use once a day for the treatment of HIV/AIDS as new dosage forms.
- Open Access
- 12 January 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (6) , 4-12
The Rational Regional Schedule of Preventive Vaccinations
Relevance. The National vaccination schedule (NVS) of the Russian Federation includes 12 infections against 17–18 indicated in the Vaccination Schedules of most EU countries, and requires improvement in terms of expanding the number of infections and contingents subject to immunization, which is reflected in the «Strategy for the development of vaccine prevention of infectious diseases for the period up to 2035» and the roadmap for its implementation. Since the process of entry of new infections and new vaccines into NVS is quite «difficult» and economically costly (development of domestic vaccines, modernization of domestic enterprises, localization of production of foreign vaccines at Russian enterprises, formation of commitment of medical workers and public confidence in new immunobiological medicines), part of the tasks is to ensure public accessibility to vaccine prevention of infections not indicated in the The NVS can be successfully solved within the framework of regional vaccination schedules (RVS).Aims. To propose and interpret the concept of rational regional vaccination schedules, and also to outline the principles of its formation and assessment of the immediate and long-term prospects for the development of regional foundations of vaccination prevention.Results and discussion. RVS is an expanded version of NVS by including additional vaccine-controlled infections, taking into account the epidemic situation and the presence of high-risk groups of infection in the region. In modern conditions, RVS have been developed and are effectively used in a number of subjects of the Russian Federation, such as Moscow, Perm Krai, Sverdlovsk, Chelyabinsk, Tyumen Regions, Yamalo-Nenets Autonomous District, etc. The implementation of vaccine prophylaxis in the regions using this tool provides conditions for equal access of children and adults to modern highly effective vaccines, increases public awareness of the benefits and risks of vaccination and the level of population immunity, contributes to improving mechanisms for providing citizens with immunobiological drugs and the formation of epidemic well-being in the region based on a risk-based approach.Conclusions. In accordance with this paradigm, the authors introduce and interpret the concept of an «Rational regional vaccination schedules», define the basic principles of its formation and assess the short- and long-term prospects for the development of the regional foundations of vaccination.
- 12 January 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (6) , 4-12
Open AccessThe Rational Regional Schedule of Preventive Vaccinations
Relevance. The National vaccination schedule (NVS) of the Russian Federation includes 12 infections against 17–18 indicated in the Vaccination Schedules of most EU countries, and requires improvement in terms of expanding the number of infections and contingents subject to immunization, which is reflected in the «Strategy for the development of vaccine prevention of infectious diseases for the period up to 2035» and the roadmap for its implementation. Since the process of entry of new infections and new vaccines into NVS is quite «difficult» and economically costly (development of domestic vaccines, modernization of domestic enterprises, localization of production of foreign vaccines at Russian enterprises, formation of commitment of medical workers and public confidence in new immunobiological medicines), part of the tasks is to ensure public accessibility to vaccine prevention of infections not indicated in the The NVS can be successfully solved within the framework of regional vaccination schedules (RVS).Aims. To propose and interpret the concept of rational regional vaccination schedules, and also to outline the principles of its formation and assessment of the immediate and long-term prospects for the development of regional foundations of vaccination prevention.Results and discussion. RVS is an expanded version of NVS by including additional vaccine-controlled infections, taking into account the epidemic situation and the presence of high-risk groups of infection in the region. In modern conditions, RVS have been developed and are effectively used in a number of subjects of the Russian Federation, such as Moscow, Perm Krai, Sverdlovsk, Chelyabinsk, Tyumen Regions, Yamalo-Nenets Autonomous District, etc. The implementation of vaccine prophylaxis in the regions using this tool provides conditions for equal access of children and adults to modern highly effective vaccines, increases public awareness of the benefits and risks of vaccination and the level of population immunity, contributes to improving mechanisms for providing citizens with immunobiological drugs and the formation of epidemic well-being in the region based on a risk-based approach.Conclusions. In accordance with this paradigm, the authors introduce and interpret the concept of an «Rational regional vaccination schedules», define the basic principles of its formation and assess the short- and long-term prospects for the development of the regional foundations of vaccination.
- Open Access
- 10 May 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (2) , 90-101
Preventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants
Background. Registration of combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in Russia necessitates studies on its preventive efficacy, safety, immunogenic activity, and post-vaccination responses following the immunization of premature infants. Objective. The aim of the study is to evaluate efficacy, safety, and immunogenic activity of combined trivalent vaccine (measles-rubella-parotitis) and level of post-vaccination responses following the immunization of premature infants. Methods. Experimental studies were conducted to evaluate safety, immunogenicity, and postvaccinal responses after immunization of premature infants with combined within prospective comparative clinical observation. Results. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has shown: no cases of measles, rubella or parotitis among vaccinated persons within prospective clinical observation for 2 years; no disturbances in parameters of clinical blood analysis, biochemical blood count, total IgE, IgA, IgM, IgG (immunogram), or urine analysis among vaccinated children over time; no subjective perceptions, adverse events signs at physical examination among vaccinated compared to baseline parameters; low post-vaccination reactions (6.7%) and similar tolerance of trivalent vaccine Vaktrivir among full-term infants (3.3%) (p = 0.301). Conclusion. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has demonstrated high safety profile and immunogenic properties for measles, rubella and parotitis components, good tolerability, and low post-vaccination responses after immunization, comparable to vaccination of full-term infants.
- 10 May 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (2) , 90-101
Open AccessPreventive Efficacy, Safety, Immunogenic Activity, and Evaluation of Post-Vaccination Responses Following Immunization with Combined Trivalent Vaccine Vaktrivir (Measles-Rubella-Parotitis) in Premature Infants
Background. Registration of combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in Russia necessitates studies on its preventive efficacy, safety, immunogenic activity, and post-vaccination responses following the immunization of premature infants. Objective. The aim of the study is to evaluate efficacy, safety, and immunogenic activity of combined trivalent vaccine (measles-rubella-parotitis) and level of post-vaccination responses following the immunization of premature infants. Methods. Experimental studies were conducted to evaluate safety, immunogenicity, and postvaccinal responses after immunization of premature infants with combined within prospective comparative clinical observation. Results. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has shown: no cases of measles, rubella or parotitis among vaccinated persons within prospective clinical observation for 2 years; no disturbances in parameters of clinical blood analysis, biochemical blood count, total IgE, IgA, IgM, IgG (immunogram), or urine analysis among vaccinated children over time; no subjective perceptions, adverse events signs at physical examination among vaccinated compared to baseline parameters; low post-vaccination reactions (6.7%) and similar tolerance of trivalent vaccine Vaktrivir among full-term infants (3.3%) (p = 0.301). Conclusion. Administration of the combined trivalent vaccine Vaktrivir (measles-rubella-parotitis) in premature infants has demonstrated high safety profile and immunogenic properties for measles, rubella and parotitis components, good tolerability, and low post-vaccination responses after immunization, comparable to vaccination of full-term infants.
- Open Access
- 3 April 2023
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 100 (1) , 65-73
Standard definition of a clinical case of mumps and diagnostic effectiveness of the test systems used in the modern period
Introduction. Registration of regular epidemic outbreaks of mumps infection among young people, difficulties in the clinical diagnosis of the disease, the presence of specific clinical manifestations in adults with a severe course of infection make it necessary the improvement of the quality of diagnosis of the disease. The aim of the work is to develop a standard definition of a clinical case of mumps and to conduct a comparative assessment of the effectiveness of the diagnostic test systems used for mumps diagnostics based on the determination of their sensitivity and specificity. Materials and methods. To develop a standard definition of a clinical case of mumps based on ten combined clinical and laboratory parameters, a mathematical model was built using the logistic regression method. The study included 84 patients with mumps infection (main group) and 66 patients with non-epidemic sialoadenitis (comparison group). For a comparative evaluation of the diagnostic systems VectoParotitis-IgM, VectoParotitis-IgG, ELISA-Mumps-IgM, ELISA-Mumps-IgG, Anti-Mumps Virus ELISA-IgM, and Anti-Mumps Virus ELISA-IgG, a blood serum samples from patients (n = 41) with a diagnosis mumps? were tested in dynamics to assess their sensitivity, specificity, and diagnostic effectiveness. Results. The clinical symptom dry mouth increased the chance of diagnosing mumps by 13.7 times, the presence of bilateral lesions of the salivary glands by 6.5 times, the increase in the level of diastase in the urine by 3.2 times. The coefficient of determination R2 was 61.1; the sensitivity was 93% and the specificity 67%; p 0.001. Diagnostic effectiveness of Anti-Mumps Virus ELISA-IgG test system was 84.4%, ELISA-Mumps-IgG 87.2%, and "VectoParotitis-IgG" 88.5%. Conclusions. Based on the combination of following clinical symptoms observed simultaneously in patient, of the general weakness, dry mouth, bilateral lesions of the salivary glands, an increase in the level of diastase in the urine, it is possible to establish a clinical diagnosis of mumps with a probability of 81%. The highest diagnostic effectiveness of domestically manufactured test systems for quantitation of IgG antibodies to mumps virus in sick people has been demonstrted.
- 3 April 2023
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 100 (1) , 65-73
Open AccessStandard definition of a clinical case of mumps and diagnostic effectiveness of the test systems used in the modern period
Introduction. Registration of regular epidemic outbreaks of mumps infection among young people, difficulties in the clinical diagnosis of the disease, the presence of specific clinical manifestations in adults with a severe course of infection make it necessary the improvement of the quality of diagnosis of the disease. The aim of the work is to develop a standard definition of a clinical case of mumps and to conduct a comparative assessment of the effectiveness of the diagnostic test systems used for mumps diagnostics based on the determination of their sensitivity and specificity. Materials and methods. To develop a standard definition of a clinical case of mumps based on ten combined clinical and laboratory parameters, a mathematical model was built using the logistic regression method. The study included 84 patients with mumps infection (main group) and 66 patients with non-epidemic sialoadenitis (comparison group). For a comparative evaluation of the diagnostic systems VectoParotitis-IgM, VectoParotitis-IgG, ELISA-Mumps-IgM, ELISA-Mumps-IgG, Anti-Mumps Virus ELISA-IgM, and Anti-Mumps Virus ELISA-IgG, a blood serum samples from patients (n = 41) with a diagnosis mumps? were tested in dynamics to assess their sensitivity, specificity, and diagnostic effectiveness. Results. The clinical symptom dry mouth increased the chance of diagnosing mumps by 13.7 times, the presence of bilateral lesions of the salivary glands by 6.5 times, the increase in the level of diastase in the urine by 3.2 times. The coefficient of determination R2 was 61.1; the sensitivity was 93% and the specificity 67%; p 0.001. Diagnostic effectiveness of Anti-Mumps Virus ELISA-IgG test system was 84.4%, ELISA-Mumps-IgG 87.2%, and "VectoParotitis-IgG" 88.5%. Conclusions. Based on the combination of following clinical symptoms observed simultaneously in patient, of the general weakness, dry mouth, bilateral lesions of the salivary glands, an increase in the level of diastase in the urine, it is possible to establish a clinical diagnosis of mumps with a probability of 81%. The highest diagnostic effectiveness of domestically manufactured test systems for quantitation of IgG antibodies to mumps virus in sick people has been demonstrted.
- Open Access
- 15 September 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (4) , 95-102
Domestic Tetravaccine (Measles-Rubella-Mumps) – Immunization of Premature Babies
Relevance. According to WHO experts, in the world every year more than 10% of children (about 15 million) are born prematurely. Premature births have a high risk of adverse course of infectious diseases, including vaccine-preventable diseases due to insufficient maternal antibodies, active transmission of which occurs in the third semester of pregnancy. Aim. To study the tolerability of Vactrivir® vaccine in infants born prematurely. Materials and methods. The children (mean age 1.7 ± 0.6 years, born prematurely with a body weight of less than 2500 g) included in the study group participated in the study. The control group consisted of years born at term and comparable in sex and age with the children in the study group. Results. The administration of Vaktrivir® vaccine to infants born prematurely confirmed the high safety profile of the drug. There were no deviations from the norm in general and biochemical blood tests, general urinalysis, and the content of immunoglobulins IgA, IgM, IgG, IgE in the dynamics. There were no undesirable side effects in the postvaccination period, which confirms good tolerability of the drug. Conclusion. In practice, the high safety profile and good tolerability of the domestic tetravaccine Vaktrivir® for immunization of premature infants have been confirmed.
- 15 September 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (4) , 95-102
Open AccessDomestic Tetravaccine (Measles-Rubella-Mumps) – Immunization of Premature Babies
Relevance. According to WHO experts, in the world every year more than 10% of children (about 15 million) are born prematurely. Premature births have a high risk of adverse course of infectious diseases, including vaccine-preventable diseases due to insufficient maternal antibodies, active transmission of which occurs in the third semester of pregnancy. Aim. To study the tolerability of Vactrivir® vaccine in infants born prematurely. Materials and methods. The children (mean age 1.7 ± 0.6 years, born prematurely with a body weight of less than 2500 g) included in the study group participated in the study. The control group consisted of years born at term and comparable in sex and age with the children in the study group. Results. The administration of Vaktrivir® vaccine to infants born prematurely confirmed the high safety profile of the drug. There were no deviations from the norm in general and biochemical blood tests, general urinalysis, and the content of immunoglobulins IgA, IgM, IgG, IgE in the dynamics. There were no undesirable side effects in the postvaccination period, which confirms good tolerability of the drug. Conclusion. In practice, the high safety profile and good tolerability of the domestic tetravaccine Vaktrivir® for immunization of premature infants have been confirmed.
- Open Access
- 15 July 2022
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 39 (3) , 83-89
Standard determination of clinical case of measles in conditions of its elimination
Objective. To develop a standard determination of a clinical case of measles in conditions of its elimination. Materials and methods. The study included 28 patients with measles (main group) and 30 with infectious mononucleosis (comparison group). By means of correlation analysis, among clinicolaboratory indicators there was determined a list of clinical signs, which statistically significantly were more often identified in patients with measles compared to patients with infectious mononucleosis. The mathematical model was developed using the method of logistic regression, which helped to single out the most qualitative binary classifiers directly connected with diagnostic probability of measles. Sensitivity and specificity of the obtained model were calculated. For statistical processing IBM SPSS Statistics 26 was used. Results. To carry out a standard determination of a clinical case of measles with the presence of combined clinicolaboratory symptoms, the mathematical model was developed, described by the following equation: р=1/(1+е-z) · 100, where z=71,7+36,8 · Х dry cough +53,5 · Х maculo-papular rash +17,6 · Х damages of eyes in the form of conjunctivitis and/or sclerite. Taking into account the regression coefficient values, such clinicolaboratory symptoms as maculo-papular rash, damages of eyes in the form of conjunctivitis and/or sclerite were directly connected with diagnostic probability of the diagnosis “Measles”. The determination coefficient of the obtained model was R2 = 0,97, p < 0,001. The sensitivity of the model was 96.4 %, specificity – 100 %, efficiency – 98 %. Conclusions. In conditions of measles elimination, the combination of maculo-papular rash, damages of eyes in the form of conjunctivitis and/or sclerite allows confirming the clinical diagnosis of measles with the probability of 98 %.
- 15 July 2022
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 39 (3) , 83-89
Open AccessStandard determination of clinical case of measles in conditions of its elimination
Objective. To develop a standard determination of a clinical case of measles in conditions of its elimination. Materials and methods. The study included 28 patients with measles (main group) and 30 with infectious mononucleosis (comparison group). By means of correlation analysis, among clinicolaboratory indicators there was determined a list of clinical signs, which statistically significantly were more often identified in patients with measles compared to patients with infectious mononucleosis. The mathematical model was developed using the method of logistic regression, which helped to single out the most qualitative binary classifiers directly connected with diagnostic probability of measles. Sensitivity and specificity of the obtained model were calculated. For statistical processing IBM SPSS Statistics 26 was used. Results. To carry out a standard determination of a clinical case of measles with the presence of combined clinicolaboratory symptoms, the mathematical model was developed, described by the following equation: р=1/(1+е-z) · 100, where z=71,7+36,8 · Х dry cough +53,5 · Х maculo-papular rash +17,6 · Х damages of eyes in the form of conjunctivitis and/or sclerite. Taking into account the regression coefficient values, such clinicolaboratory symptoms as maculo-papular rash, damages of eyes in the form of conjunctivitis and/or sclerite were directly connected with diagnostic probability of the diagnosis “Measles”. The determination coefficient of the obtained model was R2 = 0,97, p < 0,001. The sensitivity of the model was 96.4 %, specificity – 100 %, efficiency – 98 %. Conclusions. In conditions of measles elimination, the combination of maculo-papular rash, damages of eyes in the form of conjunctivitis and/or sclerite allows confirming the clinical diagnosis of measles with the probability of 98 %.
- Open Access
- 3 March 2022
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 19 (1) , 6-19
Comparative Analysis of Immunization and Immunization Coverage in Children of Russian Federation Federal Districts
Background. One of the effective ways to maintain the epidemic well-being of vaccine preventable diseases is to estimate immunization rates and coverage.Objective. The aim of the study is to conduct comparative analysis of immunization levels among children in various regions of Russian Federation. Methods. Children aged from 6 months to 15 years conducted comparative analysis of indicators of documented immunization and immunization coverage according to forms 112/y and 036/y in four federal districts of Russian Federation. The immunization rate was estimated in individuals who had completed vaccination scheme according to the national immunization schedule (NIS) (of 2014). Immunization coverage was estimated by number of persons with at least one vaccination in past medical history.Results. The analysis was performed on 2687 children medical records from the Central, Ural, Siberian and Volga federal districts (FD). BCG immunization rates in all FDs tend to be 100%. There are high levels of immunization against hepatitis B, as well as against measles, rubella and parotitis (the lowest values are noted in the Central Federal District: against hepatitis B — 74%, against measles, rubella, mumps — 69%, high — in the Volga Federal District: against hepatitis B — 95%, against measles, rubella, mumps — 97%). There is significant mismatch in immunization rates and immunization coverage for pertussis, diphtheria, tetanus and poliomyelitis in all FDs (from 20% to 40%) indicating that there are disturbances in vaccination schemes. Low immunization rates are noted against pneumococcal infection (from 12% in the Siberian Federal District to 36% in the Volga Federal District) and influenza (from 0.5% in the Volga Federal District to 9% in the Ural Federal District).Conclusion. The highest immunization rates for all infections included in the NIS (apart from influenza) were revealed in the Volga Federal District. Influenza immunization rate is critically low in all FDs.
- 3 March 2022
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 19 (1) , 6-19
Open AccessComparative Analysis of Immunization and Immunization Coverage in Children of Russian Federation Federal Districts
Background. One of the effective ways to maintain the epidemic well-being of vaccine preventable diseases is to estimate immunization rates and coverage.Objective. The aim of the study is to conduct comparative analysis of immunization levels among children in various regions of Russian Federation. Methods. Children aged from 6 months to 15 years conducted comparative analysis of indicators of documented immunization and immunization coverage according to forms 112/y and 036/y in four federal districts of Russian Federation. The immunization rate was estimated in individuals who had completed vaccination scheme according to the national immunization schedule (NIS) (of 2014). Immunization coverage was estimated by number of persons with at least one vaccination in past medical history.Results. The analysis was performed on 2687 children medical records from the Central, Ural, Siberian and Volga federal districts (FD). BCG immunization rates in all FDs tend to be 100%. There are high levels of immunization against hepatitis B, as well as against measles, rubella and parotitis (the lowest values are noted in the Central Federal District: against hepatitis B — 74%, against measles, rubella, mumps — 69%, high — in the Volga Federal District: against hepatitis B — 95%, against measles, rubella, mumps — 97%). There is significant mismatch in immunization rates and immunization coverage for pertussis, diphtheria, tetanus and poliomyelitis in all FDs (from 20% to 40%) indicating that there are disturbances in vaccination schemes. Low immunization rates are noted against pneumococcal infection (from 12% in the Siberian Federal District to 36% in the Volga Federal District) and influenza (from 0.5% in the Volga Federal District to 9% in the Ural Federal District).Conclusion. The highest immunization rates for all infections included in the NIS (apart from influenza) were revealed in the Volga Federal District. Influenza immunization rate is critically low in all FDs.